Technical Analysis for CNTB - Connect Biopharma Holdings Limited

Grade Last Price % Change Price Change
C 1.74 8.07% 0.13
CNTB closed up 8.07 percent on Thursday, March 28, 2024, on 3.31 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: Apr 15
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
Expansion Breakout Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Calm After Storm Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%

   Recent Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Connect Biopharma Holdings Limited Description

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Immunology Immune System Immunotherapy Inflammation Asthma Atopic Dermatitis Chronic Rhinosinusitis Human Physiology Skin Inflammation Animal Physiology Interleukins Nasal Polyps

Is CNTB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.84
52 Week Low 0.5347
Average Volume 141,811
200-Day Moving Average 1.10
50-Day Moving Average 1.23
20-Day Moving Average 1.29
10-Day Moving Average 1.35
Average True Range 0.16
RSI (14) 70.93
ADX 20.01
+DI 39.42
-DI 8.82
Chandelier Exit (Long, 3 ATRs) 1.50
Chandelier Exit (Short, 3 ATRs) 1.57
Upper Bollinger Bands 1.58
Lower Bollinger Band 1.01
Percent B (%b) 1.28
BandWidth 44.10
MACD Line 0.08
MACD Signal Line 0.03
MACD Histogram 0.0453
Fundamentals Value
Market Cap 95.82 Million
Num Shares 55.1 Million
EPS -1.56
Price-to-Earnings (P/E) Ratio -1.12
Price-to-Sales 0.00
Price-to-Book 0.47
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.20
Resistance 3 (R3) 2.23 2.10 2.13
Resistance 2 (R2) 2.10 1.98 2.09 2.10
Resistance 1 (R1) 1.92 1.91 2.01 1.89 2.07
Pivot Point 1.79 1.79 1.83 1.78 1.79
Support 1 (S1) 1.61 1.67 1.70 1.59 1.41
Support 2 (S2) 1.48 1.60 1.47 1.38
Support 3 (S3) 1.30 1.48 1.36
Support 4 (S4) 1.28